Unknown

Dataset Information

0

Augmented IL-15R? expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.


ABSTRACT: IL-15 has potential as an immunotherapeutic agent for cancer treatment because it is a critical factor for the proliferation and activation of NK and CD8(+) T cells. However, monotherapy of patients with malignancy with IL-15 that has been initiated may not be optimal, because of the limited expression of the private receptor, IL-15R?. We demonstrated greater CD8 T cell-mediated therapeutic efficacy using a combination regimen of murine IL-15 administered with an agonistic anti-CD40 Ab (FGK4.5) that led to increased IL-15R? expression on dendritic cells (DCs), as well as other cell types, in a syngeneic established TRAMP-C2 tumor model. Seventy to one hundred percent of TRAMP-C2 tumor-bearing wild-type C57BL/6 mice in the combination group manifested sustained remissions, whereas only 0-30% in the anti-CD40-alone group and none in the murine IL-15-alone group became tumor free (p < 0.001). However, the combination regimen showed less efficacy in TRAMP-C2 tumor-bearing IL-15R?(-/-) mice than in wild-type mice. The combination regimen significantly increased the numbers of TRAMP-C2 tumor-specific SPAS-1/SNC9-H(8) tetramer(+)CD8(+) T cells, which were associated with the protection from tumor development on rechallenge with TRAMP-C2 tumor cells. Using an in vitro cytolytic assay that involved NK cells primed by wild-type or IL-15R?(-/-) bone marrow-derived DCs, we demonstrated that the expression of IL-15R? by DCs appeared to be required for optimal IL-15-induced NK priming and killing. These findings support the view that anti-CD40-mediated augmented IL-15R? expression was critical in IL-15-associated sustained remissions observed in TRAMP-C2 tumor-bearing mice receiving combination therapy.

SUBMITTER: Zhang M 

PROVIDER: S-EPMC3370156 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Zhang Meili M   Ju Wei W   Yao Zhengsheng Z   Yu Ping P   Wei Bih-Rong BR   Simpson R Mark RM   Waitz Rebecca R   Fassò Marcella M   Allison James P JP   Waldmann Thomas A TA  

Journal of immunology (Baltimore, Md. : 1950) 20120516 12


IL-15 has potential as an immunotherapeutic agent for cancer treatment because it is a critical factor for the proliferation and activation of NK and CD8(+) T cells. However, monotherapy of patients with malignancy with IL-15 that has been initiated may not be optimal, because of the limited expression of the private receptor, IL-15Rα. We demonstrated greater CD8 T cell-mediated therapeutic efficacy using a combination regimen of murine IL-15 administered with an agonistic anti-CD40 Ab (FGK4.5)  ...[more]

Similar Datasets

| S-EPMC5705392 | biostudies-literature
| S-EPMC1482584 | biostudies-literature
| S-EPMC7218419 | biostudies-literature
| S-EPMC4941302 | biostudies-literature
| S-EPMC6258921 | biostudies-literature
| S-EPMC3746870 | biostudies-other
| S-EPMC4060713 | biostudies-other
| S-EPMC153623 | biostudies-literature
2021-07-27 | GSE178142 | GEO
| S-EPMC10569074 | biostudies-literature